Greenway Partners LP recently announced the acquisition of new stake in Lineage Cell Therapeutics Inc. (AMEX:LCTX). The institutional investor has increased its shareholding in the Healthcare company by 3.14% to 6.84 million shares with purchase of 0.21 million shares. This fresh investment now brings its stake to 4.57% valued currently at $5.61 million. In addition, Defender Capital LLC raised its holdings by 0.23 million to 4.65 million shares. And Jane Street Capital LLC has lifted its position by 424.48% or 0.81 million shares – to 1.0 million shares.
With over 1.06 million Lineage Cell Therapeutics Inc. (LCTX) shares trading Monday and a closing price of $0.92 on the day, the dollar volume was approximately $0.98 million. The shares have shown a positive weekly performance of 5.15% and its price on 08/31/20 gained nearly 1.67%. Currently, there are 149.82M common shares owned by the public and among those 142.41M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for LCTX have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $3.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Lineage Cell Therapeutics Inc. stock is 2.20 for the next 12 months. But an upside of 86.86% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 123,600 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 42,743 shares.
The top 3 mutual fund holders in Lineage Cell Therapeutics Inc. are Vanguard Total Stock Market Index, British & American Investment Tru, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 3.43 million shares of the company’s stock, all valued at over $2.81 million. British & American Investment Tru sold 37561.0 shares to see its total holdings shrink to 2.15 million shares valued at over $1.76 million and representing 1.44% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 1.02% of the shares outstanding.
Shares of Lineage Cell Therapeutics Inc. (AMEX: LCTX) opened at $0.92, up $0.02 from a prior closing price of $0.90. However, the script later closed the day at $0.92, up 1.67%. The company’s stock has a 5-day price change of 5.15% and 0.55% over the past three months. LCTX shares are trading 2.81% year to date (YTD), with the 12-month market performance down to -2.08% lower. It has a 12-month low price of $0.53 and touched a high of $1.67 over the same period. Currently, 1.06 million shares have been traded, compared to an average intraday trading volume of 1.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.28%, 5.40%, and 2.43% respectively.
Institutional ownership of Lineage Cell Therapeutics Inc. (AMEX: LCTX) shares accounts for 37.20% of the company’s 149.82M shares outstanding. Mutual fund holders own 4.53%, while other institutional holders and individual stakeholders account for 8.39% and 35.01% respectively.
It has a market capitalization of $133.59M and a beta (3y monthly) value of 2.13. The earnings-per-share (ttm) stands at -$0.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.59% over the week and 6.62% over the month.
Analysts forecast that Lineage Cell Therapeutics Inc. (LCTX) will achieve an EPS of -$0.04 for the current quarter, -$0.04 for the next quarter and -$0.16 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.05 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.11 a year ago. Earnings per share for the fiscal year are expected to increase by 77.80%, and 11.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Lineage Cell Therapeutics Inc. (LCTX) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 1 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”